Literature DB >> 14551241

Does nitric oxide mediate the vasodilator activity of nitroglycerin?

Andrei L Kleschyov1, Matthias Oelze, Andreas Daiber, Yale Huang, Hanke Mollnau, Eberhard Schulz, Karsten Sydow, Birgit Fichtlscherer, Alexander Mülsch, Thomas Münzel.   

Abstract

Nitroglycerin (glyceryl trinitrate, GTN) relaxes blood vessels primarily via activation of the soluble guanylyl cyclase (sGC)/cGMP/cGMP-dependent protein kinase (cGK-I) pathway. Although the precise mechanism of sGC activation by GTN in the vascular wall is unknown, the mediatory role of nitric oxide (NO) has been postulated. We tested the GTN/NO hypothesis in different types of isolated rat and rabbit blood vessels using two novel approaches: (1) EPR spin trapping using colloid Fe(DETC)2 and (2) analysis of cGK-I-dependent phosphorylation of the vasodilator-stimulated phosphoprotein at Ser239 (P-VASP). For comparison, another organic nitrate, isosorbide dinitrate (ISDN), and endothelium-dependent vasodilator, calcium ionophore A23187, were tested. We found a marked discrepancy between GTN's strong vasoactivity (vasodilation and augmentation of P-VASP) and its poor NO donor properties. In aortas precontracted with phenylephrine, GTN, ISDN, and A23187 induced nearly full relaxations (>80%) and doubling of vascular P-VASP content at concentrations of 100 nmol/L, 100 micromol/L, and 1 micromol/L, respectively. GTN applied in vasorelaxant concentrations (10 to 1000 nmol/L) did not significantly increase the basal vascular NO production, in contrast to ISDN and A23187. The absence of GTN-derived NO was confirmed in rabbit vena cava and renal artery. A significant increase in vascular NO formation was observed only at suprapharmacological GTN concentrations (>10 micromol/L). The concentration dependency of NO formation from GTN was comparable to that of ISDN, although the latter exhibits 100-folds lower vasorelaxant potency. We conclude that GTN activates the sGC/cGMP/cGK-I pathway and induces vasorelaxation without intermediacy of the free radical NO. The full text of this article is available online at http://www.circresaha.org.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551241     DOI: 10.1161/01.RES.0000100067.62876.50

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  49 in total

Review 1.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

2.  Number of nitrate groups determines reactivity and potency of organic nitrates: a proof of concept study in ALDH-2-/- mice.

Authors:  P Wenzel; U Hink; M Oelze; A Seeling; T Isse; K Bruns; L Steinhoff; M Brandt; A L Kleschyov; E Schulz; K Lange; H Weiner; J Lehmann; K J Lackner; T Kawamoto; T Münzel; A Daiber
Journal:  Br J Pharmacol       Date:  2007-01-15       Impact factor: 8.739

3.  Plasma detection of NO by a catheter.

Authors:  Masami Goto; Seiichi Mochizuki
Journal:  Med Biol Eng Comput       Date:  2008-05       Impact factor: 2.602

4.  Effect of chronic sodium nitrite therapy on monocrotaline-induced pulmonary hypertension.

Authors:  Edward A Pankey; Adeleke M Badejo; David B Casey; George F Lasker; Russel A Riehl; Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz
Journal:  Nitric Oxide       Date:  2012-03-14       Impact factor: 4.427

5.  Nitroglycerin drives endothelial nitric oxide synthase activation via the phosphatidylinositol 3-kinase/protein kinase B pathway.

Authors:  Mao Mao; Varadarajan Sudhahar; Kristine Ansenberger-Fricano; Denise C Fernandes; Leonardo Y Tanaka; Tohru Fukai; Francisco R M Laurindo; Ronald P Mason; Jeannette Vasquez-Vivar; Richard D Minshall; Krisztian Stadler; Marcelo G Bonini
Journal:  Free Radic Biol Med       Date:  2011-10-07       Impact factor: 7.376

6.  Effects of the nitric oxide donor, sodium nitroprusside, on resting leg glucose uptake in patients with type 2 diabetes.

Authors:  D C Henstridge; B A Kingwell; M F Formosa; B G Drew; G K McConell; S J Duffy
Journal:  Diabetologia       Date:  2005-11-05       Impact factor: 10.122

7.  Effect of oral organic nitrates on expression and activity of vascular soluble guanylyl cyclase.

Authors:  M Oppermann; V T-V Dao; T Suvorava; M Bas; G Kojda
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

8.  Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule.

Authors:  Roberta Foresti; Jehad Hammad; James E Clark; Tony R Johnson; Brian E Mann; Andreas Friebe; Colin J Green; Roberto Motterlini
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

9.  Role of the general base Glu-268 in nitroglycerin bioactivation and superoxide formation by aldehyde dehydrogenase-2.

Authors:  M Verena Wenzl; Matteo Beretta; Antonius C F Gorren; Andreas Zeller; Pravas K Baral; Karl Gruber; Michael Russwurm; Doris Koesling; Kurt Schmidt; Bernd Mayer
Journal:  J Biol Chem       Date:  2009-06-08       Impact factor: 5.157

10.  Characterization of the East Asian variant of aldehyde dehydrogenase-2: bioactivation of nitroglycerin and effects of Alda-1.

Authors:  Matteo Beretta; Antonius C F Gorren; M Verena Wenzl; Robert Weis; Michael Russwurm; Doris Koesling; Kurt Schmidt; Bernd Mayer
Journal:  J Biol Chem       Date:  2009-11-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.